One-Time gene therapy aims to free Wilson's patients from daily pills

NCT ID NCT04537377

First seen Jan 31, 2026 · Last updated May 24, 2026 · Updated 15 times

Summary

This early-stage trial tests a single dose of gene therapy (VTX-801) in 4 adults with Wilson's disease, a genetic condition causing copper buildup. The goal is to see if it's safe and can control copper levels well enough to let patients stop their daily medications. Participants will be followed for up to 5 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WILSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Aarhus University Hospital

    Aarhus, 8200, Denmark

  • Advent Health

    Orlando, Florida, 32803, United States

  • Royal Surrey County Hospital

    Guildford, Surrey, GU2 7XX, United Kingdom

  • UC Davis Medical Center

    Sacramento, California, 95817, United States

  • University Hospital Essen

    Essen, 45147, Germany

  • University of Michigan Health System

    Ann Arbor, Michigan, 48109, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75235, United States

  • Universitätsklinikum Tübingen (UKT)

    Tübingen, 72076, Germany

  • Wake Forest School of Medicine

    Winston-Salem, North Carolina, 27157, United States

  • Yale University School of Medecine

    New Haven, Connecticut, 06510, United States

Conditions

Explore the condition pages connected to this study.